Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

August 24, 2021

Study Completion Date

August 24, 2021

Conditions
CoronaVirus Disease-2019 (COVID-19)
Interventions
DRUG

ABBV-47D11

Intravenous (IV) infusion.

DRUG

Placebo for ABBV-47D11

Intravenous (IV) infusion.

DRUG

ABBV-2B04

Intervenous (IV) Infusion

DRUG

Placebo for ABBV-2B04

Intervenous (IV) Infusion

Trial Locations (18)

1023

Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz /ID# 226015, Budapest

1085

Semmelweis Egyetem /ID# 226016, Budapest

33136

University of Miami /ID# 225038, Miami

45219

The Christ Hospital /ID# 224541, Cincinnati

52621

Sheba Medical Center /ID# 225857, Tel Hashomer, Ramat Gan

91120

Hadassah Medical Center-Hebrew University /ID# 225827, Jerusalem

91206-4007

Glendale Adventist Medical Center /ID# 225188, Glendale

33157-6608

Beautiful Minds Clinical Research Center /ID# 228708, Cutler Bay

33407-3100

Triple O Research Institute /ID# 228612, West Palm Beach

60612-7232

University of Illinois Hospital and Health Sciences System /ID# 224323, Chicago

41501-1689

Pikeville Medical Center /ID# 224539, Pikeville

08901-1766

Saint Peter's University Hospital /ID# 225183, New Brunswick

07102

Saint Michael's Medical Center /ID# 225258, Newark

29605-4210

Prisma Health Children's Hospital Upstate /ID# 224556, Greenville

77702-1100

Gadolin Research, LLC /ID# 229394, Beaumont

3584 CX

Universitair Medisch Centrum Utrecht /ID# 225919, Utrecht

00726

San Juan Bautista School of Medicine /ID# 225963, Caguas

00674

Manati Medical Center /ID# 225936, Manatí

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY